Expert Interview
Discussing the use of HIF-2α inhibitors in RCC, with a focus on updated data on Arcus Biosciences' casdatifan in the ARC-20 trial and Merck's belzutifan in the LITESPARK-011 trial
Ticker(s): RCUS, MRKInstitution: Moffitt
- Genitourinary Oncologist and Interim Vice Chair at Moffitt, Clinical research director of Moffitt Cancer center's geniourinary program.
- Manages 350 patients with prostate cancer.
- Primary Research interests is integrating tumor evolution dynamics into the treatment of advanced prostate cancer, and has been PI and co-investigator in >50 clinical studies since 2010.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
